BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform. The company was originally founded as NanoBio Corporation, a spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation and NIH contracts, the company underwent a strategic pivot in 2016-17 to refocus its nanotechnology platform on the development of intranasal vaccines for respiratory and sexually transmitted diseases.